Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week High – Here’s What Happened

Posted by Stanley Muller on Aug 11th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $27.13 and last traded at $26.8390, with a volume of 92718 shares changing hands. The stock had previously closed at $26.50.

Wall Street Analyst Weigh In

DYN has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein upped their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Morgan Stanley reduced their price target on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a report on Thursday, July 23rd. They set an “overweight” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.42.

Get Our Latest Report on Dyne Therapeutics

Dyne Therapeutics Price Performance

The firm has a 50-day simple moving average of $22.15 and a 200-day simple moving average of $19.26. The firm has a market capitalization of $5.00 billion, a PE ratio of -8.01 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Brian S. Posner bought 2,000 shares of Dyne Therapeutics stock in a transaction on Monday, June 8th. The stock was acquired at an average cost of $16.94 per share, with a total value of $33,880.00. Following the completion of the acquisition, the director owned 24,500 shares in the company, valued at approximately $415,030. This represents a 8.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Erick Lucera sold 2,362 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares in the company, valued at $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders acquired 9,000 shares of company stock worth $156,800 and sold 1,558,819 shares worth $34,385,234. 9.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter valued at about $26,000. Strs Ohio bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after acquiring an additional 7,697 shares during the period. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.